Drug Trial Radar · NCT06513949
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jun 17, 2026
Primary completion
Mar 1, 2029
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- Implicit BioscienceIndustry
- Sponsor type
- Industry
- Collaborators
- University of Washington
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Conditions
- Acute Respiratory Distress Syndrome
- Adult Respiratory Distress Syndrome
- Acute Lung Injury
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
AtibuclimabBiological
monoclonal antibody against human CD14
PlaceboOther
Sterile normal saline for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Day 4 Oxygenation IndexTime frame: Day 1 through Day 4
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harborview Medical Center
Seattle, Washington · Recruiting
University of Washington
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.